Epstein-Barr Virus (VCA) IgA ELISA Kit (Human)
Cat# OKNA00133
Size : 96Wells
Marca : Aviva Systems Biology
Epstein-Barr Virus (VCA) IgA ELISA Kit (Human) (OKNA00133)
| Datasheets/Manuals | Click here to download product manual. As variation between lots may occur, always reference the lot-specific manual received with each kit. |
|---|
| Predicted Species Reactivity | Human | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ELISA Kit Detection Method | Colorimetric, OD450 nm | |||||||||||||||||||||||||||||
| ELISA Kit Duration | ~3 Hours | |||||||||||||||||||||||||||||
| ELISA Kit Principle | Aviva Systems Biology Epstein-Barr Virus (VCA) IgA ELISA Kit (Human) (OKNX00133) is based on standard reverse capture sandwich enzyme-linked immuno-sorbent assay technology. Epstein-Barr Virus antigen has been pre-coated and blocked in a 96-wellplate (12 x 8 Well Strips). Standards or test samples are added to the wells, incubated and washed. An HRP conjugated detector antibody specific for Human IgA is added, incubated and followed by washing. An enzymatic reaction is produced through the addition of substrate which is catalyzed by HRP generating a blue color product that changes to yellow after adding acidic stop solution. The density of yellow coloration is read by absorbance at 450 nm and is qualitatively proportional to the amount of sample anti-Epstein-Barr Virus IgA captured the in well. | |||||||||||||||||||||||||||||
| ELISA Kit Reproducibility |
| |||||||||||||||||||||||||||||
| ELISA Kit Component |
| |||||||||||||||||||||||||||||
| Reconstitution and Storage | Store as indicated in product manual. | |||||||||||||||||||||||||||||
| Sample Type | Serum, Plasma | |||||||||||||||||||||||||||||
| Assay Info | Assay Methodology: Quantitative Reverse Capture Sandwich ELISA |
| Alias Symbols | VCA |
|---|---|
| Protein Name | Epstein-Barr Virus IgA |
| Description of Target | Epstein-Barr Virus (EBV) is a member of the herpes virus family (Gamma subgroup, DNA virus of 120-200 nm) and one of the most common human viruses. The virus occurs worldwide, and most people become infected with EBV sometime during their lives. Transmission of the virus is almost impossible to prevent since many healthy people can carry and spread the virus intermittently for life. Infants become susceptible to EBV as soon as maternal antibody protection disappears. Infection of children usually causes no symptoms. Infection during adolescence or young adulthood causes infectious mononucleosis 35% to 50% of the time. Infectious mononucleosis is almost never fatal. There are no known associations between active EBV infection and problems during pregnancy, such as miscarriages or birth defects. Although the symptoms of infectious mononucleosis usually resolve in 1 or 2 months, EBV remains dormant or latent in a few cells in the throat and blood for the rest of the person’s life. Periodically, the virus can reactivate and is commonly found in the saliva of infected persons. This reactivation usually occurs without symptoms of illness. EBV also establishes a lifelong dormant infection in some cells of the body’s immune system. A late event in a very few carriers of this virus is the emergence of Burkitt´s lymphoma and nasopharyngeal carcinoma, but EBV is probably not the sole cause of these malignancies. |